Literature DB >> 9357519

Inhibition of tubulin polymerization by 5,6-dihydroindolo[2,1-alpha]isoquinoline derivatives.

M Goldbrunner1, G Loidl, T Polossek, A Mannschreck, E von Angerer.   

Abstract

6-Alkyl-12-formyl-5,6-dihydroindolo[2,1-alpha]isoquinolines have been shown to inhibit the growth of human mammary carcinoma cells by an unknown mode of action. One of the possible molecular targets is the tubulin system which is involved in cell division. A number of 5,6-dihydroindolo[2,1-alpha]isoquinolines with methoxy or hydroxy groups in positions 3, 9, and/or 10 and various functional groups such as formyl, acetyl, cyano, alkylimino, and alkylamino in position 12 were synthesized and evaluated for both inhibition of tubulin polymerization and cytostatic activity in MDA-MB 231 and MCF-7 human breast cancer cells. In the tubulin polymerization assay, only hydroxy derivatives were active, whereas both the hydroxy derivatives and some of the methoxy compounds inhibited cell growth. In order to establish a correlation between the inhibition of tubulin polymerization and cytostatic activity in the hydroxy series, two of the most active racemates were separated into the enantiomers. In both assays, the relative potencies of the hydroxy derivatives were in a similar order. Highest activity was found for the (+)-isomers of 6-propyl- (6b) and 6-butyl-12-formyl-5,6-hydro-3,9-dihydroxyindolo[2,1-alpha]isoquino line (6c) with IC50 values of 11 +/- 0.4 and 3.1 +/- 0.4 microM, respectively, for the polymerization of tubulin at 37 degrees C (colchicine: 2.1 +/- 0.1 microM). The active hydroxy derivatives displaced 40-70% of [3H]colchicine from its binding site in the tubulin at concentrations 10-fold higher than that of colchicine. The data suggest that hydroxy-substituted indolo[2,1-alpha]isoquinolines bind to the colchicine-binding site and inhibit the polymerization of tubulin. This action can be assumed to be responsible for the cytostatic activity of the hydroxy derivatives and might also contribute to the antitumor effect of the corresponding methyl ethers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9357519     DOI: 10.1021/jm970177c

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Selective partial reduction of various heteroaromatic compounds with bridgehead nitrogen via Birch reduction protocol.

Authors:  Joseph T Kim; Vladimir Gevorgyan
Journal:  J Org Chem       Date:  2005-03-18       Impact factor: 4.354

2.  An intramolecular cascade cyclization of 2-aryl indoles: efficient methods for the construction of 2,3-functionalized indolines and 3-indolinones.

Authors:  Arun K Ghosh; Zhi-Hua Chen
Journal:  Org Biomol Chem       Date:  2014-05-01       Impact factor: 3.876

3.  An efficient solvent-free synthesis of 2-(alkylamino)-2-oxo-1-arylethyl-6,12-dioxo-6,12-dihydroindolo[1,2-b]isoquinoline-11-carboxylate derivatives via four-component reaction.

Authors:  Tahmineh Kenarkoohi; Abbas Rahmati
Journal:  Mol Divers       Date:  2019-01-05       Impact factor: 2.943

4.  Synthesis of pyrido[1,2-a]indole malonates and amines through aryne annulation.

Authors:  Donald C Rogness; Nataliya A Markina; Jesse P Waldo; Richard C Larock
Journal:  J Org Chem       Date:  2012-03-06       Impact factor: 4.354

5.  Mechanisms by which synthetic 6,7-annulated-4-substituted indole compounds with anti-proliferative activity disrupt mitosis and block cytokinesis in human HL-60 tumor cells in vitro.

Authors:  Jean-Pierre H Perchellet; Elisabeth M Perchellet; Chingakham Ranjit Singh; Meghan T Monnett; Elizabeth R Studer; Paul D Thornton; Neil Brown; David Hill; Ben Neuenswander; Gerald H Lushington; Conrad Santini; Keith R Buszek
Journal:  Anticancer Res       Date:  2014-04       Impact factor: 2.480

Review 6.  The Anticancer Effect of Natural Plant Alkaloid Isoquinolines.

Authors:  Dahye Yun; So Young Yoon; Soo Jung Park; Yoon Jung Park
Journal:  Int J Mol Sci       Date:  2021-02-06       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.